STUB1 and therapy-related myeloid neoplasm: An association with IMiD maintenance and subsequent therapy-related myeloid neoplasm (TMN) was noted (p = 0.047), but the presence of CHIP prior to ASCT was not associated with increased risk of TMN (p = 0.4) regardless of whether IMiD maintenance was administered [42].